Intervet sees 6% global growth

Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.

In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.

Sign up for our
regular news updates

Latest Industry News

•   Britain Makes the Switch to Sustainable Species
•   Council Supports Local Oyster Industry
•   EU Approves Block Exemption for State Aid
•   500 Marine Protected Areas Established in Philippines
•   Parliament Passes Fisheries Bill
•   Scottish Fishermenn Maintain Pressure over Fuel
•   Update on Ganglioneuritis Virus in Abalone
•   Lack of Fish Farming Policy Force Prices Down
•   Governor Impressed by Seafood Industry
•   New Zealand Fast Forward Bold Step Forward